Kinnate Biopharma Inc. to Present Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference
Kinnate Biopharma (Nasdaq: KNTE) has announced details of its first in human trial (KN-8701) for KIN-2787, a pan-RAF inhibitor targeting multiple BRAF mutations in solid tumors. The trial is actively recruiting patients and will be presented at the AACR-NCI-EORTC Conference from October 7-10, 2021. KIN-2787 aims to offer a first-line targeted therapy option for patients with lung cancer, melanoma, and other tumors. The first patient has commenced treatment at the Sarah Cannon Research Institute, highlighting ongoing collaborations in this critical clinical study.
- None.
- None.
The KN-8701 trial is a multi-center, open-label, two-part trial of Kinnate’s lead RAF inhibitor candidate KIN-2787
SAN FRANCISCO and SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that details of the trial design and scientific rationale for its first in human (FIH) Phase 1/1b trial (KN-8701: NCT04913285) evaluating KIN-2787 has been selected for a poster presentation at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021.
KIN-2787, Kinnate’s most advanced product candidate, is an orally available small molecule pan-RAF inhibitor being developed for the treatment of patients with lung cancer, melanoma, and other solid tumors. Unlike currently available treatments that target only Class I BRAF kinase mutations, Kinnate has designed KIN-2787 to target Class II and Class III BRAF alterations, where it has the potential to be a first-line targeted therapy, in addition to covering Class I BRAF mutations.
“We are looking forward to sharing additional details of the KN-8701 trial which is actively recruiting at the first three centers in the United States with additional centers planned to activate soon,” said Richard Williams, MBBS, Ph.D., Chief Medical Officer of Kinnate. “The first patient in this trial commenced treatment at Sarah Cannon Research Institute at Tennessee Oncology and we appreciate their ongoing collaboration in this important clinical trial of KIN-2787.”
The poster (#P226), titled “Design and rationale of a first in human (FIH) Phase 1/1b study evaluating KIN-2787, a potent and highly selective pan-RAF inhibitor, in adult patients with BRAF mutation positive solid tumors,” will be delivered by co-investigator Meredith McKean, MD, MPH, Associate Director, Melanoma and Skin Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology.
Additional information on the AACR-NCI-EORTC Virtual International Conference can be found online at: https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics.
For more information on the KN-8701 trial, please visit www.kinnate.com/patients.
About Kinnate
Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors. For more information, please visit www.kinnate.com.
Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. These forward-looking statements include, without limitation, statements regarding the potential benefits of our product candidates and the enrollment and conduct of our clinical trials. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are also intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends. Such expectations and projections may never materialize or may prove to be incorrect. These forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors, including risks related to operating as a preclinical-stage biopharmaceutical company with a limited operating history; our ability to raise additional capital to finance our operations; our ability to discover, advance through the preclinical and clinical development of, obtain regulatory approval for and commercialize our product candidates; the novel approach we are taking to discover and develop drugs; our ability to timely file and obtain approval of investigational new drug applications for our planned clinical trials; the potential for any clinical trial results to differ from our preclinical trial results; negative impacts of the COVID-19 pandemic on our business, including planned clinical trials and ongoing and planned preclinical trials; competition in our industry; regulatory developments in the United States and other countries; our ability to attract, hire and retain highly skilled executive officers and employees; difficulties in managing our growth; our ability to protect our intellectual property; reliance on third parties to conduct our preclinical studies and any future clinical trials, and to manufacture our product candidates; general economic and market conditions; and other risks.
These and other risks, uncertainties, assumptions and other factors are further described under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021 that we have filed with the Securities and Exchange Commission (the “SEC”), as well as in our subsequent filings we make with the SEC. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. Investors should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Our forward-looking statements speak only as of the date of this release, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason in the future.
Contacts:
Investors:
Patti Bank
Westwicke, an ICR Company
415-513-1284
investors@kinnate.com
Media:
Colin Sanford
203-918-4347
colin@bioscribe.com
FAQ
What is the KN-8701 trial for KNTE?
When is the AACR-NCI-EORTC conference where KNTE will present?
What types of cancer is KIN-2787 intended to treat?
Where is the first patient of the KN-8701 trial being treated?
What mutations does KIN-2787 target?
